Cardiovascular drugs have been unsuccessful investments in recent years, but this one makes sense.
News & Analysis: MyoKardia
The transaction will give Bristol Myers Squibb a potential first-in-class cardiovascular drug with blockbuster expectations.
President Trump's condition remains a focal point among market participants.
The heart disease specialist fetches a rather rich buyout offer from Bristol Myers Squibb.
MYOK earnings call for the period ending June 30, 2020.
Solid phase 3 data from MyoKardia’s lead drug candidate drove share gains.
A phase 3 victory for MyoKardia’s lead drug candidate may lead to more wins down the road.
The company's experimental heart drug hit the mark in a pivotal study.
These drug developers just released new clinical trial results.
MYOK earnings call for the period ending December 31, 2019.